494 related articles for article (PubMed ID: 27913457)
1. Treatment of blastic plasmacytoid dendritic cell neoplasm.
Sullivan JM; Rizzieri DA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):16-23. PubMed ID: 27913457
[TBL] [Abstract][Full Text] [Related]
2. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
3. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
4. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects.
Trottier AM; Cerquozzi S; Owen CJ
Blood Lymphat Cancer; 2017; 7():85-93. PubMed ID: 31360087
[TBL] [Abstract][Full Text] [Related]
5. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
6. Myeloid Cell Nuclear Differentiation Antigen (MNDA) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm.
Johnson RC; Kim J; Natkunam Y; Sundram U; Freud AG; Gammon B; Cascio MJ
Am J Surg Pathol; 2016 Apr; 40(4):502-9. PubMed ID: 26796502
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.
Kharfan-Dabaja MA; Lazarus HM; Nishihori T; Mahfouz RA; Hamadani M
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1006-12. PubMed ID: 23396213
[TBL] [Abstract][Full Text] [Related]
8. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.
Laribi K; Denizon N; Besançon A; Farhi J; Lemaire P; Sandrini J; Truong C; Ghnaya H; Baugier de Materre A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1357-1367. PubMed ID: 27026248
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
12. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
13. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm.
Cronin DM; George TI; Reichard KK; Sundram UN
Am J Clin Pathol; 2012 Mar; 137(3):367-76. PubMed ID: 22338048
[TBL] [Abstract][Full Text] [Related]
15. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
Wang S; Wang X; Liu M; Bai O
Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
17. [Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face].
Ahogo KC; Wantz M; Cliquennois M; Gosset P; Lebas D; Modiano P
Ann Dermatol Venereol; 2014 Jan; 141(1):43-7. PubMed ID: 24461094
[TBL] [Abstract][Full Text] [Related]
18. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
19. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
[TBL] [Abstract][Full Text] [Related]
20. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
